Literature DB >> 15118844

MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.

Xiaoyuan Chen1, Ryan Park, Yingping Hou, Vazgen Khankaldyyan, Ignacio Gonzales-Gomez, Michel Tohme, James R Bading, Walter E Laug, Peter S Conti.   

Abstract

We have previously labeled cyclic RGD peptide c(RGDyK) with fluorine-18 through conjugation labeling via a prosthetic 4-[18F]fluorobenzoyl moiety and applied this [18F]FB-RGD radiotracer for alphav-integrin expression imaging in different preclinical tumor models with good tumor-to-background contrast. However, the unfavorable hepatobiliary excretion and rapid tumor washout rate of this tracer limit its potential clinical applications. The aims of this study were to modify the [18F]FB-RGD tracer by inserting a heterobifunctional poly(ethylene glycol) (PEG, M.W. =3,400) between the 18F radiolabel and the RGD moiety and to test this [18F]FB-PEG-RGD tracer for brain tumor targeting and in vivo kinetics. [18F]FB-PEG-RGD was prepared by coupling the RGD-PEG conjugate with N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) under slightly basic conditions (pH=8.5). The radiochemical yield was about 20-30% based on the active ester [18F]SFB, and specific activity was over 100 GBq/micromol. This tracer had fast blood clearance, rapid and high tumor uptake in the subcutaneous U87MG glioblastoma model (5.2+/-0.5%ID/g at 30 min p.i.). Moderately rapid tumor washout was observed, with the activity accumulation decreased to 2.2+/-0.4%ID/g at 4 h p.i. MicroPET and autoradiography imaging showed a very high tumor-to-background ratio and limited activity accumulation in the liver, kidneys and intestinal tracts. U87MG tumor implanted into the mouse forebrain was well visualized with [18F]FB-PEG-RGD. Although uptake in the orthotopic tumor was significantly lower (P<0.01) than in the subcutaneous tumor, the maximum tumor-to-brain ratio still reached 5.0+/-0.6 due to low normal brain background. The results of H&E staining post mortem agreed with the anatomical information obtained from non-invasive microPET imaging. In conclusion, PEGylation suitably modifies the physiological behavior of the RGD peptide. [18F]FB-PEG-RGD gave improved tumor retention and in vivo kinetics compared with [18F]FB-RGD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118844     DOI: 10.1007/s00259-003-1452-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo alpha(v)beta3 integrin related tumor imaging.

Authors:  Mikako Ogawa; Kentaro Hatano; Shinya Oishi; Yasuhiro Kawasumi; Nobutaka Fujii; Michiya Kawaguchi; Ryuichiro Doi; Masayuki Imamura; Mikio Yamamoto; Keiichi Ajito; Takahiro Mukai; Hideo Saji; Kengo Ito
Journal:  Nucl Med Biol       Date:  2003-01       Impact factor: 2.408

2.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.

Authors:  D A Sipkins; D A Cheresh; M R Kazemi; L M Nevin; M D Bednarski; K C Li
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

3.  Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Authors:  R Haubner; H J Wester; U Reuning; R Senekowitsch-Schmidtke; B Diefenbach; H Kessler; G Stöcklin; M Schwaiger
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

4.  Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.

Authors:  P M van Hagen; W A Breeman; H F Bernard; M Schaar; C M Mooij; A Srinivasan; M A Schmidt; E P Krenning; M de Jong
Journal:  Int J Cancer       Date:  2000-08-20       Impact factor: 7.396

5.  Cytostatic Agents in the Management of Malignant Gliomas.

Authors: 
Journal:  Cancer Control       Date:  1998-03       Impact factor: 3.302

6.  Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting.

Authors:  Marcel Janssen; Wim J G Oyen; Leon F A G Massuger; Cathelijne Frielink; Ingrid Dijkgraaf; D Scott Edwards; Milind Radjopadhye; Frans H M Corstens; Otto C Boerman
Journal:  Cancer Biother Radiopharm       Date:  2002-12       Impact factor: 3.099

Review 7.  Angiogenesis in brain tumors.

Authors:  M Beatriz S Lopes
Journal:  Microsc Res Tech       Date:  2003-02-01       Impact factor: 2.769

Review 8.  Molecular epidemiology of glioblastoma.

Authors:  Kenneth D Aldape; M Fatih Okcu; Melissa L Bondy; Margaret Wrensch
Journal:  Cancer J       Date:  2003 Mar-Apr       Impact factor: 3.360

9.  A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation.

Authors:  H J Wester; K Hamacher; G Stöcklin
Journal:  Nucl Med Biol       Date:  1996-04       Impact factor: 2.408

Review 10.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

View more
  44 in total

1.  Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2.

Authors:  Xianzhong Zhang; Zhengming Xiong; Yun Wu; Weibo Cai; Jeffery R Tseng; Sanjiv S Gambhir; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-01       Impact factor: 10.057

2.  Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice.

Authors:  Zhen Cheng; Yun Wu; Zhengming Xiong; Sanjiv Sam Gambhir; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2005 Nov-Dec       Impact factor: 4.774

Review 3.  Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?

Authors:  Roland Haubner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07       Impact factor: 9.236

4.  Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates.

Authors:  Karin A Stephenson; Rajesh Chandra; Zhi-Ping Zhuang; Catherine Hou; Shunichi Oya; Mei-Ping Kung; Hank F Kung
Journal:  Bioconjug Chem       Date:  2007 Jan-Feb       Impact factor: 4.774

5.  Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers.

Authors:  Yun Wu; Weibo Cai; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

6.  A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression.

Authors:  Weibo Cai; Xianzhong Zhang; Yun Wu; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2006-07       Impact factor: 10.057

Review 7.  Positron emission tomography imaging of cancer biology: current status and future prospects.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

8.  Microwave-assisted one-pot synthesis of N-succinimidyl-4[ ¹⁸F]fluorobenzoate ([¹⁸F]SFB).

Authors:  Shuang Hou; Duy Linh Phung; Wei-Yu Lin; Ming-wei Wang; Kan Liu; Clifton Kwang-Fu Shen
Journal:  J Vis Exp       Date:  2011-06-28       Impact factor: 1.355

9.  Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers.

Authors:  Zhaofei Liu; Shuanglong Liu; Fan Wang; Shuang Liu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-19       Impact factor: 9.236

10.  An engineered knottin peptide labeled with 18F for PET imaging of integrin expression.

Authors:  Zheng Miao; Gang Ren; Hongguang Liu; Richard H Kimura; Lei Jiang; Jennifer R Cochran; Sanjiv Sam Gambhir; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2009-12       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.